[Market Focus] G2GBIO Surges on Obesity Drug Shortage and Boehringer Joint Development Highlight

As the obesity treatment drug Mounjaro faces a supply shortage, shares of G2GBIO are showing strong performance. This appears to be due to the company's production capabilities for obesity treatments and its ongoing collaborations with overseas pharmaceutical companies.

As of 1:54 p.m. on September 12, 2025, G2GBIO shares were trading at 174,600 won, up 5.24% from the previous day.

Founded in 2017, G2GBIO specializes in sustained-release injectable drug delivery platforms. Its proprietary drug delivery technology, the "InnoLAMP" platform, stands out for its overwhelming productivity of 30 to 60 kilograms per batch, achieved through direct emulsification and continuous solvent removal technologies.

The obesity injection treatment Mounjaro, launched last month, continues to experience shortages even four weeks after its release, confirming strong demand for obesity treatments. As a result, expectations are rising for the subcutaneous injectable obesity treatment being developed by Boehringer Ingelheim, with which G2GBIO has signed a contract. If development is successful, it is expected that G2GBIO's production volume will increase as it competes with drugs like Mounjaro and Wegovy.

Previously, G2GBIO signed a long-acting injectable formulation contract with Boehringer Ingelheim in January and secured an additional contract in August. The company has also entered into joint development agreements with two global big pharma companies. In addition, the global boom in GLP-1-based treatments is expected to benefit G2GBIO.